SCHEMBL2647057

SCHEMBL2647057

NNc1cc(N2CCCC2)c(Cl)nn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
POLB P06746 4/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 2/20 0.37
GFER P55789 1/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 4/20 0.36
CASP1 P29466 2/20 0.36
HSD17B10 Q99714 2/20 0.36
APAF1 O14727 1/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.36
CASP3 P42574 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
CASP7 P55210 1/20 0.36
SMAD3 P84022 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655169 0.94 ALDH1A1 (0.40) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL2646163 0.85 MAPT (0.44) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL7984107 0.80 ALDH1A1 (0.32) ALDH1A1MAPTGAA
SCHEMBL31226115 0.79 ALDH1A1 (0.33) ALDH1A1MAPTGAA
SCHEMBL2648429 0.76 CYP1A2 (0.46) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL2646178 0.74 CYP1A2 (0.48) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL30893809 0.74 CYP1A2 (0.48) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL6784562 0.71 SENP6 (0.56) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL6784565 0.71 SENP6 (0.56) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL7962272 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6699859-B1 TREATMENT OF ANXIETY AND CONVULSIONS. MERCK SHARP & DOHME LTD. (GB) 2004-03-02 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed
EP-1150983-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2001-11-07 EP disclosed
US-6303605-B1 FOR THERAPY OF ANXIETY AND CONVULSIONS MERCK SHARP & DOHME LTD. (GB) 2001-10-16 US disclosed
US-6291460-B1 TREATMENT OF ANXIETY; TREATMENT AND/OR PREVENTION OF CONVULSIONS MERCK SHARP & DOHME LIMITED (GB) 2001-09-18 US disclosed
EP-1056748-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-12-06 EP disclosed
EP-1056746-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-12-06 EP disclosed
EP-1049698-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-11-08 EP disclosed
EP-1049696-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-11-08 EP disclosed
WO-2000047582-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2000-08-17 WO disclosed
WO-1999037646-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed
WO-1999037644-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed
WO-1999037648-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed
WO-1999037647-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 ALDH1A1 1373/4885POLB 4237/4885MEN1 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.